SELLAS Life Sciences Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

NeuVax (nelipepimut-S) / Dr. Reddy’s

VADIS, NCT02636582: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Completed

Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, E75 Plus GM-CSF, E75 Vaccine Plus GM-CSF, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF, Nelipepimut-S Plus Sargramostim, NeuVax Plus GM-CSF, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery

National Cancer Institute (NCI)

Breast Ductal Carcinoma In Situ

07/19

05/23

Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine

LYTPET, NCT00324467: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Active, not recruiting

150

Canada

Cyclophosphamide, Cytoxan®, Neosar®, Doxorubicin, Adriamycin ®, Rubex®, Vincristine, Oncovin ®, Vincasar Pfs ®, Vincristine Sulfate, LCR, VCR, Prednisone, Sterapred®, Sterapred® DS, Prednisone Intensol, Ondansetron, Zofran®, Zofran® ODT, Zuplenz®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak® Taperpak®, Diphenhydramine, Aler-Dryl®, Benadryl®, Nytol®, Diphenhist®, Acetaminophen, Tylenol®, Ifosfamide, Ifex®, Isophosphamide, Mesna (IV), Mesnex®, Sodium 2-mercaptoethanesulfonate, Mesna (oral), Carboplatin, CBDCA, Etoposide, Etopophos®, VP-16, Rituximab, Rituxan®, PET Scan, Positron emission tomography (PET) scan

British Columbia Cancer Agency, Hoffmann-La Roche

Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma

12/21

NCT03030417: Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Completed

LMP744, NSC 706744, Ondansetron, Zofran ODT, Zuplenz, Zofran, Olanzapine, Zyprexa Relprevv, Zyprexa Zydis, Zyprexa, Lorazepam, Lorazepam Intensol, Ativan, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Lomocot, Lomotil, Lonox, Vi-Atro, Loperamide, Imodium A-d, Diamode, Anti-Diarrheal (loperamide), Diphenhydramine, Benadryl, Nytol, Banophen, Steroid, Epinephrine, Adrenaline

National Cancer Institute (NCI)

Solid Tumors, Lymphoma

10/23

NCT06175806: Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group

Completed

N/A

160

RoW

Ondansetron Oral Film, Granisetron Oral Liquid Product

Ain Shams University

Nausea and Vomiting in Pediatric Age Group

11/23

Zeltherva (galinpepimut-S) / SELLAS Life Sciences

REGAL, NCT04229979 / 2019-004134-42: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruiting

128

Europe, US, RoW

Galinpepimut-S, SLS-001, GPS, Azacitidine, Venetoclax, Decitabine, Cytarabine, Ara-C, Observation, GM-CSF, sargramostim, Montanide

Sellas Life Sciences Group

Acute Myeloid Leukemia

12/24

03/25

NCT01890980: Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

Active, not recruiting

WT-1-vaccine Montanide + GM-CSF, Montanide adjuvant + GM-CSF

M.D. Anderson Cancer Center, U.S. Army Medical Research and Materiel Command, Memorial Sloan Kettering Cancer Center, Sellas Life Sciences Group

Malignant Pleural Mesothelioma

04/20

04/21

NCT03761914: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Completed

1/2

galinpepimut-S, SLS-001, GPS, WT1 Analog Peptide Vaccine, pembrolizumab, MK-3475, Keytruda, Montanide, GM-CSF, sargramostim

Sellas Life Sciences Group, Merck Sharp & Dohme LLC, LumaBridge

Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer

07/22

10/22

NCT05320809: Study of 3D189 in Patients With Hematologic Malignancies

Active, not recruiting

RoW

3D189

3D Medicines

Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome

12/24

NCT04040231: Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma

Completed

Galinpepimut-S, Nivolumab, Sargramostim, GM-CSF

Memorial Sloan Kettering Cancer Center

Mesothelioma, Pleural Mesothelioma, Wilms Tumor

11/24

NCT05593185: Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Available

N/A

Galinpepimut-S

Sellas Life Sciences Group

Acute Myeloid Leukemia, Myelodysplastic Syndromes

SLS009 / SELLAS Life Sciences

NCT06375733: A Study of GFH009 in Combination with Zanubrutinib in Subjects with Relapsed or Refractory DLBCL

Recruiting

1/2

RoW

GFH009, Zanubrutinib

Genfleet Therapeutics (Shanghai) Inc.

Large B-cell Lymphoma

12/26

GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

Recruiting

1/2

160

US, RoW

SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine

Sellas Life Sciences Group, Sellas Life Sciences Group

Hematologic Malignancies

06/25

12/25

NCT05934513: A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Recruiting

1/2

RoW

GFH009

Genfleet Therapeutics (Shanghai) Inc.

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

12/25

06/26



	Diseases Companies Products Productz Mechanisms of Action Sites